Regen BioPharma, Inc. (RGBP)
| Previous close | 0.0051 |
| Open | 0.0052 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0042 - 0.0060 |
| 52-week range | 0.0034 - 0.0815 |
| Volume | |
| Avg. volume | 32,926,995 |
| Market cap | 23.206M |
| Beta (5Y monthly) | 3.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0170 |
| Earnings date | 20 Jan 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has an extensive intellectual property portfolio consisting of granted patents, published applications and pending applications. Regen, and its wholly-owned subsidiary KCL Therapeutics, Inc., own the following patent portfolio:
- PR Newswire
Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen's existing siRNA ( small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
- PR Newswire
Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the development program, Regen will design and have experiments carried out that will form the initial series of pre-clinical studies required as part of an FDA IND submission.
